Who is sponsoring NCT04826185?

NCT04826185 is sponsored by Imbria Pharmaceuticals, Inc..

What drugs are being tested in NCT04826185?

Interventions in NCT04826185: IMB-1018972, Placebo.

What condition does NCT04826185 study?

NCT04826185 studies Non-obstructive Hypertrophic Cardiomyopathy.

Is NCT04826185 still recruiting?

NCT04826185 is currently completed. Last updated 23 April 2024.

Last reviewed 2024-04-23 · How we verify

NCT04826185: IMPROVE-HCM

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients With Non-obstructive Hypertrophic Cardiomyopathy Trial

Completed Phase 2 Last updated 23 April 2024

What this trial tests

Phase 2 trial testing IMB-1018972 in Non-obstructive Hypertrophic Cardiomyopathy in 67 participants. Completed in 18 September 2023.

Timeline

14 June 2021

Primary endpoint
18 September 2023

18 September 2023

Quick facts

Lead sponsor	Imbria Pharmaceuticals, Inc.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	67
Start date	14 June 2021
Primary completion	18 September 2023
Estimated completion	18 September 2023
Sites	14 locations across United Kingdom, United States

Drugs / interventions tested

IMB-1018972 — full drug profile →
Placebo

Conditions studied

Non-obstructive Hypertrophic Cardiomyopathy — all drugs for Non-obstructive Hypertrophic Cardiomyopathy →

Sponsor

Imbria Pharmaceuticals, Inc. — full company profile →

Who can join

Adults 18 to 80, any sex, with Non-obstructive Hypertrophic Cardiomyopathy. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, and potential efficacy of IMB-1018972 in patients with non-obstructive HCM.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Electrophysiological mechanisms underlying T wave pseudonormalisation on stress ECGs in hypertrophic cardiomyopathy.
Coleman JA, Doste R, Beltrami M, Coppini R, et al · · 2024 · cited 6× · PMID 38096763 · DOI 10.1016/j.compbiomed.2023.107829
Clinical Trials in Hypertrophic Cardiomyopathy Therapy: A Comprehensive Analysis of Trials Registered in Global Clinical Databases.
Zhang H, Yu C, Cheng Y, Chen Z, et al · · 2023 · cited 4× · PMID 37377648 · DOI 10.2147/dddt.s413136

Verify or expand the search:

Other trials of IMB-1018972

Trials testing the same drug.

NCT04826172 — Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstru · Phase 2 · completed
NCT04826159 — IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) · Phase 2 · completed

Other recruiting trials for Non-obstructive Hypertrophic Cardiomyopathy

Currently open trials in the same condition.

NCT05569382 — Treatment Effects of Bisoprolol and Verapamil in Symptomatic Patients With Non-obstructive Hypertrophic Cardiomyopathy · Phase 4 · recruiting

Other Imbria Pharmaceuticals, Inc. trials

Trials by the same sponsor.

NCT04826172 — Exploratory Study on the Safety, Tolerability, and Pharmacodynamics of IMB-1018972 in Subjects With Angina Due to Obstru · Phase 2 · completed
NCT04826159 — IMPROVE-DiCE: Study to Evaluate Effect of IMB-1018972 on Cardiac Energetics in T2DM & Obesity (Pt 1) With HFpEF (Pt 2) · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04826185 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Imbria Pharmaceuticals, Inc.
Last refreshed: 23 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04826185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing